Medical Stocks

Charles River Laboratories Intl Inc Valuation – Initial Coverage $CRL

Benjamin Graham taught that Intelligent Investors must do a thorough fundamental analysis of investment opportunities to determine their intrinsic value and inherent risk.  This is best done by utilizing a systematic approach to analysis that will provide investors with a sense of how a specific company compares to another company or by reviewing the 10 Stocks for Using A Benjamin Graham Value Investing Strategy – February 2017.  By using the ModernGraham method one can review a company’s historical accomplishments and determine an intrinsic value that can be compared across industries.  What follows is a stock analysis showing a specific look at how Charles River Laboratories Intl Inc (CRL) fares in the ModernGraham valuation model.

Company Profile (obtained from Google Finance): Charles River Laboratories International, Inc. is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services. It has developed a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support its clients from target identification through preclinical development.

CRL Chart

CRL data by YCharts

[level-free]
To read the details of this valuation, you must be logged in as a premium member. If you are not a premium member, please consider becoming one.

Premium members can view a full ModernGraham valuation of the company and have access to download a PDF version of the valuation for easy reference. Recent valuations of the components of the Dow Jones Industrial Average are available for free members, including this one of Microsoft Corporation.  In addition, here is a post detailing what can be found within each individual company’s valuation.

Learn More About Premium Membership

[/level-free]
[not-level-free]

Downloadable PDF version of this valuation:

ModernGraham Valuation of CRL – February 2017

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $4,196,777,882 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.53 Fail
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Fail
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end -199.21% Fail
6. Moderate PEmg Ratio PEmg < 20 24.36 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 5.07 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.53 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 0.00 Pass
3. Earnings Stability Positive EPS for 5 years prior Pass
4. Dividend Record Currently Pays Dividend Fail
5. Earnings Growth EPSmg greater than 5 years ago Pass

Stage 2: Determination of Intrinsic Value

EPSmg $3.63
MG Growth Estimate 15.00%
MG Value $139.88
Opinion Undervalued
MG Grade B-
MG Value based on 3% Growth $52.68
MG Value based on 0% Growth $30.88
Market Implied Growth Rate 7.93%
Current Price $88.50
% of Intrinsic Value 63.27%

Charles River Laboratories Intl. Inc is suitable for the Enterprising Investor but not the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, the poor dividend history, and the high PEmg and PB ratios. The Enterprising Investor is only concerned with the lack of dividends. As a result, all Enterprising Investors following the ModernGraham approach should feel comfortable proceeding with the analysis.

As for a valuation, the company appears to be Undervalued after growing its EPSmg (normalized earnings) from $1.07 in 2013 to an estimated $3.63 for 2017. This level of demonstrated earnings growth outpaces the market’s implied estimate of 7.93% annual earnings growth over the next 7-10 years. As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value above the price.

At the time of valuation, further research into Charles River Laboratories Intl. Inc revealed the company was trading above its Graham Number of $44.36. The company does not pay a dividend. Its PEmg (price over earnings per share – ModernGraham) was 24.36, which was below the industry average of 32.29, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-25.4.

Charles River Laboratories Intl. Inc performs fairly well in the ModernGraham grading system, scoring a B-.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$25.40
Graham Number $44.36
PEmg 24.36
Current Ratio 1.53
PB Ratio 5.07
Current Dividend $0.00
Dividend Yield 0.00%
Number of Consecutive Years of Dividend Growth 0

[/not-level-free]

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2016
Total Current Assets $656,832,000
Total Current Liabilities $429,593,000
Long-Term Debt $0
Total Assets $2,711,800,000
Intangible Assets $1,181,965,000
Total Liabilities $1,875,032,000
Shares Outstanding (Diluted Average) 47,958,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $4.95
Dec2016 $3.23
Dec2015 $3.13
Dec2014 $2.66
Dec2013 $2.12
Dec2012 $2.01
Dec2011 $2.14
Dec2010 -$5.38
Dec2009 $1.74
Dec2008 -$7.76
Dec2007 $2.25
Dec2006 -$0.80
Dec2005 $1.96
Dec2004 $1.67
Dec2003 $1.64
Dec2002 $1.06
Dec2001 $0.80
Dec2000 -$0.35
Dec1999 $0.86
Dec1998 $2.27

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate $3.63
Dec2016 $2.86
Dec2015 $2.59
Dec2014 $1.78
Dec2013 $1.07
Dec2012 -$0.12
Dec2011 -$1.26
Dec2010 -$2.63
Dec2009 -$1.02
Dec2008 -$1.77
Dec2007 $1.26
Dec2006 $0.88
Dec2005 $1.62
Dec2004 $1.29
Dec2003 $1.00
Dec2002 $0.76
Dec2001 $0.65

Recommended Reading:

Other ModernGraham posts about the company

None. This is the first time ModernGraham has covered the company.

Other ModernGraham posts about related companies

Kindred Healthcare Inc Valuation – Initial Coverage $KND
SurModics Inc Valuation – Initial Coverage $SRDX
Agilent Technologies Inc Valuation – February 2017 $A
Cooper Companies Inc Valuation – Initial Coverage $COO
Edwards Lifesciences Corp Valuation – January 2017 $EW
Baxter International Inc Valuation – January 2017 $BAX
CONMED Corporation Valuation – Initial Coverage $CNMD
Boston Scientific Corp Valuation – January 2017 $BSX
Centene Corp Valuation – Initial Coverage $CNC
Invacare Corporation Valuation – Initial Coverage $IVC

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top